


Amendments to the Claims:

Listing of Claims:

Claims 1-22 (canceled)

Claim 23 (new): A compound of formula I



wherein

each of R⁰, R¹, R², and R³ independently is hydrogen, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkylC₁-C₈alkyl, C₅-C₁₀arylC₁-C₈alkyl, hydroxyC₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, aminoC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C₁-C₈alkoxy, hydroxyC₁-C₈alkoxy, C₁-C₈alkoxyC₁-C₈alkoxy, haloC₁-C₈alkoxy, unsubstituted or substituted C₅-C₁₀arylC₁-C₈alkoxy, unsubstituted or substituted heterocycliloxy, or unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylthio, C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; or

R⁰ and R¹, R¹ and R², and/or R² and R³ form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

R⁴ is hydrogen or C₁-C₈alkyl;

each of R⁵ and R⁶ independently is hydrogen, C₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstituted or substituted carbamoyl, cyano, or nitro; and

each of R⁷, R⁸, R⁹, and R¹⁰ independently is C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkylC₁-C₈alkyl, C₅-C₁₀arylC₁-C₈alkyl, hydroxyC₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, aminoC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C₁-C₈alkoxy, hydroxyC₁-C₈alkoxy, C₁-

C₈alkoxyC₁-C₈alkoxy, haloC₁-C₈alkoxy, unsubstituted or substituted C₅-C₁₀arylC₁-C₈alkoxy, unsubstituted or substituted heterocycloxy, or unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylthio, C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; wherein R⁷, R⁸ and R⁹ independently of each other can also be hydrogen;
 or R⁷ and R⁸, R⁸ and R⁹, and/or R⁹ and R¹⁰ form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;
 A is C or N;
 and salts thereof.

Claim 24 (new): A compound of formula I according to claim 23, wherein each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocycloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R¹ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocycloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R³ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, C₁-C₈alkoxy, substituted amino, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, unsubstituted or substituted sulfamoyl; or each pair of adjacent substituents R⁰ and R¹, or R¹ and R², or R² and R³ is -CH₂-NH-CO-, -CH₂-CH₂-NH-CO-, -CH₂-CO-NH-, -CH₂-CH₂-CO-NH-, -CH₂-NH-SO₂-, -CH₂-CH₂-NH-SO₂-, -CH₂-SO₂-NH-, -CH₂-CH₂-SO₂-NH-, -CH₂-CH₂-SO₂-, -CH₂-CH₂-CH₂-SO₂-, -O-CH₂-O-, or -O-CF₂-O-, and such pairs wherein hydrogen in NH is replaced by C₁-C₈alkyl;

R⁴ is hydrogen or C₁-C₈alkyl;

R⁵ is hydrogen; C₁-C₈alkyl, halogen, haloC₁-C₈alkyl, cyano or nitro;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R⁸ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and

R¹⁰ is C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents R⁷ and R⁸, or R⁸ and R⁹ or R⁹ and R¹⁰, is -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-O-, -CH=CH-O-, -O-CH₂-O-, or -O-CF₂-O-;

A is C or N.

Claim 25 (new): A compound of formula I according to claim 23, wherein

each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;

R¹ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen;

R³ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, C₁-C₈alkoxy, substituted amino, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents R^0 and R^1 , or R^1 and R^2 , or R^2 and R^3 is $-\text{CH}_2\text{-NH-CO}-$, $-\text{CH}_2\text{-NH-SO}_2-$, $-\text{CH}_2\text{-CH}_2\text{-SO}_2-$, $-\text{O-CH}_2\text{-O}-$, or $-\text{O-CF}_2\text{-O}-$, and such pairs wherein hydrogen in NH is replaced by $\text{C}_1\text{-C}_8\text{alkyl}$;

R^4 is hydrogen;

R^5 is hydrogen, halogen, halo $\text{C}_1\text{-C}_8\text{alkyl}$, or nitro;

R^6 is hydrogen;

each of R^7 and R^9 independently is hydrogen, $\text{C}_1\text{-C}_8\text{alkyl}$, halo $\text{C}_1\text{-C}_8\text{alkyl}$, unsubstituted or substituted $\text{C}_5\text{-C}_{10}\text{aryl}$, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $\text{C}_1\text{-C}_8\text{alkoxy}$, unsubstituted or substituted heterocycliloxy, unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R^8 is hydrogen, $\text{C}_1\text{-C}_8\text{alkyl}$, halo $\text{C}_1\text{-C}_8\text{alkyl}$, $\text{C}_5\text{-C}_{10}\text{aryl}$, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $\text{C}_1\text{-C}_8\text{alkoxy}$, halo $\text{C}_1\text{-C}_8\text{alkoxy}$, $\text{C}_5\text{-C}_{10}\text{aryloxy}$, unsubstituted or substituted heterocycliloxy, unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

R^{10} is $\text{C}_1\text{-C}_8\text{alkyl}$, halo $\text{C}_1\text{-C}_8\text{alkyl}$, $\text{C}_1\text{-C}_8\text{alkoxy}$, unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$, unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents R^7 and R^8 , or R^8 and R^9 or R^9 and R^{10} , is $-\text{NH-CH=CH}-$, $-\text{CH=CH-NH}-$, $-\text{NH-N=CH}-$, $-\text{CH=N-NH}-$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2-$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_2-$, $-\text{O-CH}_2\text{-O-}$, or $-\text{O-CF}_2\text{-O-}$;

A is C or N.

Claim 26 (new): A compound of formula I according to claim 23, wherein

each of R^0 or R^2 independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

R^1 is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R^3 is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents R^0 and R^1 , or R^1 and R^2 is $-\text{O-CH}_2\text{-O-}$, or the pair of adjacent substituents R^2 and R^3 is $-\text{CH}_2\text{-NH-CO-}$ or $-\text{CH}_2\text{-NH-SO}_2-$;

R^4 is hydrogen;

R^5 is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R^6 is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R⁸ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

R¹⁰ is C₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents R⁷ and R⁸, or R⁸ and R⁹ or R⁹ and R¹⁰, is -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -O-CH₂-O-, or -O-CF₂-O-;

A is C or N.

Claim 27 (new): A compound of formula I according to claim 23, wherein each of R⁰ or R² independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

R¹ is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R³ is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents R⁰ and R¹, or R¹ and R² is -O-CH₂-O-, or the pair of adjacent substituents R² and R³ is -CH₂-NH-CO- or -CH₂-NH-SO₂-;

R⁴ is hydrogen;

R⁵ is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

R⁸ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-

morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

R¹⁰ is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents R⁷ and R⁸ or R⁸ and R⁹ is -O-CH₂-O- or the pair of adjacent substituents R⁹ and R¹⁰ is -NH-CH=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂- or -O-CF₂-O-;

A is C or N.

Claim 28 (new): A compound of formula I according to claim 23, wherein

each of R⁰, R¹ or R² is hydrogen;

R³ is sulfamoyl, methylsulfamoyl or propylsulfamoyl;

R⁴ is hydrogen;

R⁵ is chloro or bromo;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbonyl;

R⁸ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

R¹⁰ is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents R⁷ and R⁸ or R⁸ and R⁹ is -O-CH₂-O-, or the pair of adjacent substituents R⁹ and R¹⁰ is -NH-CH=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂- or -O-CF₂-O-;


A is C or N.

Claim 29 (new): The compound of formula I according to claim 23, wherein each of R⁰, R¹ or R² is hydrogen, R³ is methylsulfamoyl, R⁴ is hydrogen, R⁵ is bromo, R⁶ is hydrogen, each of R⁷ and R⁸ is methoxy, R⁹ is hydrogen, and R¹⁰ is methyl, and A is C or N.


Claim 30 (new): The compound of formula I according to claim 23, wherein each of R⁰, R¹ or R² is hydrogen, R³ is methylsulfamoyl, R⁴ is hydrogen, R⁵ is bromo, R⁶ is hydrogen, each of R⁷ and R⁸ is hydrogen, and the pair of adjacent substituents R⁹ and R¹⁰ is -CH₂-CH₂-, and A is C or N.

Claim 31 (new): The compound of formula 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide.

Claim 32 (new): A process for the production of a compound of formula I according to claim 23, comprising reacting a compound of formula II



wherein R⁰, R¹, R², R³, R⁴, R⁵, and R⁶ are as defined in claim 23, and Y is a leaving group, with a compound of formula III



wherein R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 23;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 23, into another compound of formula I as defined in claim 23;

and recovering the resulting compound of formula I in free form or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

Claim 33 (new): A pharmaceutical composition comprising a compound according to claim 23, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

Claim 34 (new): A combination comprising a therapeutically effective amount a compound according to claim 23 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

Claim 35 (new): A method for the treatment of neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to claim 23.

Claim 36 (new): A method for the treatment or prevention of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor which comprises administering an effective amount of a compound according to claim 23.

Claim 37 (new): A method according to claim 36, wherein the disease to be treated is a proliferative disease.

Claim 38 (new): A method according to claim 37, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal , prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

Claim 39 (new): A method according to claim 35, wherein the disease to be treated is an immune disease.

Claim 40 (new): A method to treat an inflammatory and/or immune disorder comprising administering an effective amount of a compound according to claim 23 wherein the disorder is selected from transplant rejection, allergy and autoimmune disorders mediated by immune cells including T lymphocytes, B lymphocytes, macrophages, dendritic cells, mast cells and eosinophils.

Claim 41 (new): A method according to claim 35, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or a pharmaceutically acceptable salt thereof.

Claim 42 (new): A method according to claim 35, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-

sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-{5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.